Abstract: The invention is to provide a method of manufacturing a mechanical structural shaft component improved in the fatigue strength and maintained in the manufacturability, and a mechanical structural shaft component manufactured by the method. The shaft component is manufactured by blending and melting a raw material so as to achieve a steel material composition of, in % by mass, Fe: 96% or more, C: 0.45% or more and 0.55% or less, Si: 0.02% or more and 0.15% or less, Mn: more than 0.50% and 1.20% or less, P: 0.005% or more and 0.020% or less, S: 0.005% or more and 0.030% or less, Cr: 0.10% or more and 0.30% or less, Al: 0.002% or more and 0.050% or less, Ti: 0.020% or more and 0.050% or less, B: 0.0005% or more and 0.0030% or less and Nb: 0.020% or more and 0.100% or less; by allowing the raw material to solidify, while keeping cooling rate of the center portion of a bloom at 2° C./min or above; and by subjecting the resultant steel material to product rolling or forging at a heating temperature of 950° C.

Abstract: There is provided: an ignition agent composition comprising a base agent containing substantially no lead component, a combustion improver, and an additive, the composition comprising, as a base agent component, one or more materials selected from the group consisting of 5-nitroaminotetrazole and metal 5-nitroaminotetrazolate; and an igniter using the ignition agent composition.

Abstract: An igniting agent composition substantially free of a lead compound, characterized in that it comprises a metal power and one or more selected from the group consisting of nitrate salt, basic nitrate salt, a metal oxide and a basic carbonate salt; and an igniter using the igniting agent composition. The igniting agent composition shows no delay in ignition time and no reduction in igniting capability, as compared to conventional lead-containing composition.

Abstract: A gas generator S of the present invention comprises an elongated cylindrical housing 1 closed at both ends thereof, a combustion chamber 2, formed in the housing 1 at one end portion thereof, for packing gas generant 3 that is burnt to generate high temperature gas, an igniter device 5, fixed in the housing 1 at one end thereof, for igniting and burning the gas generant 3 packed in the combustion chamber 2, a filtering member 4, inserted in the housing 1 and set at the other end portion of the housing 1, and gas discharge holes 6 formed at the other end of the housing 1 to communicate between an inside of the housing 1 and an outside of the same with respect to an axial direction of the housing 1.

Abstract: A method of producing amorphous paroxetine hydrochloride, which comprises converting paroxetine or its lower alkanoic acid salt into paroxetine hydrochloride and then spray drying a solution of the hydrochloride.

Abstract: A process for producing a piperidinecarbinol represented by the general formula (2), which comprises reducing the trans isomer of a compound represented by the general formula (1): wherein R1 is a hydrogen atom, a lower alkyl group or an aralkyl group, R2 is a hydrogen atom, a lower alkyl group, an aryl group or an aralkyl group, and X is a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, a dialkylamino group, an alkylthio group, an arylthio group or CmF2m+1— wherein m is an integer of from 1 to 20.

Abstract: An automatically ignitable enhancer agent composition comprising: (a) 5-aminotetrazole, (b) a metal powder, (c) at least one compound selected from the group consisting of potassium nitrate, sodium nitrate and strontium nitrate, and (d) molybdenum trioxide, and having a heating value of 4500 J/g or more. Further, the above composition which has an ability to generate gases in an amount of 0.5 mol to 2.0 mol per 100 g of the composition is also disclosed.

Abstract: A process for producing a paroxetine represented by the following formula (4), which comprises reacting an N-alkylpiperidine represented by the following general formula (1) with a haloformic acid ester represented by the general formula (2) to prepare an alkoxycarbonylpiperidine represented by the general formula (3), and hydrolyzing the alkoxycarbonylpiperidine under alkaline conditions: 1

Abstract: A process for producing a piperidinecarbinol represented by the general formula (2), which comprises reducing the trans isomer of a compound represented by the general formula (1): wherein R1 is a hydrogen atom, a lower alkyl group or an aralkyl group, R2 is a hydrogen atom, a lower alkyl group, an aryl group or an aralkyl group, and X is a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, a dialkylamino group, an alkylthio group, an arylthio group or CmF2m+1— wherein m is an integer of from 1 to 20.

Abstract: A process for producing a paroxetine represented by the following formula (4), which comprises reacting an N-alkylpiperidine represented by the following general formula (1) with a haloformic acid ester represented by the general formula (2) to prepare an alkoxycarbonylpiperidine represented by the general formula (3), and hydrolyzing the alkoxycarbonylpiperidine under alkaline conditions: wherein each of R1 and R2 is a lower alkyl group, a lower cycloalkyl group, an aralkyl group or CmF2m+1 (wherein m is an integer of from 1 to 6), and X is a halogen atom.

Abstract: A method of producing amorphous paroxetine hydrochloride, which comprises converting paroxetine or its lower alkanoic acid salt into paroxetine hydrochloride and then spray drying a solution of the hydrochloride.

Abstract: A steel product contains, by mass %, C: 0.45 to 0.60%, Si: 0.01 to 0.15%, Mn: 0.20 to 0.60%, S: 0.012% or lower, Al: 0.015 to 0.040%, Ti: 0.005 to 0.050%, B: 0.0005 to 0.0050%, N: 0.010% or lower, O: 0.0010% or lower, and balance being Fe and unavoidable impurities. Limitations are provided to allowable maximum sizes per each sort of contained non-metallic inclusions and the number per unit area thereof. This steel may contains one kind or two kinds or more of Cr: 1.00% or lower, Mo: 0.50% or lower and Ni: 1.50 or lower.

Abstract: A process for producing a piperidinecarbinol represented by the general formula (2), which comprises reducing the trans isomer of a compound represented by the general formula (1): wherein R1 is a hydrogen atom, a lower alkyl group or an aralkyl group, R2 is a hydrogen atom, a lower alkyl group, an aryl group or an aralkyl group, and X is a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, a dialkylamino group, an alkylthio group, an arylthio group or CmF2m+1— wherein m is an integer of from 1 to 20.

Abstract: A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like.

Abstract: A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like.

Abstract: A difluoroprostacyclin of the following formula (V), its lower alkanol ester or its pharmaceutically acceptable salt: ##STR1## wherein A is an ethylene group, a vinylene group or an ethynylene group, R is a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.1-10 alkenyl group, a substituted or unsubstituted C.sub.1-10 alkynyl group, a substituted or unsubstituted C.sub.3-8 cycloalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryloxy group, Q is a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.1-10 alkenyl group, a substituted or unsubstituted C.sub.1-10 alkynyl group, a substituted or unsubstituted C.sub.3-8 cycloalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group.

Abstract: A difluoroprostacyclin of the following formula (V), its lower alkanol ester or its pharmaceutically acceptable salt: ##STR1## wherein A is an ethylene group, a vinylene group or an ethynylene group, R is a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.1-10 alkenyl group, a substituted or unsubstituted C.sub.1-10 alkynyl group, a substituted or unsubstituted C.sub.3-8 cycloalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryloxy group, Q is a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.1-10 alkenyl group, a substituted or unsubstituted C.sub.1-10 alkynyl group, a substituted or unsubstituted C.sub.3-8 cycloalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group.

Abstract: A difluoroprostacyclin of the following formula (V), its lower alkanol ester or its pharmaceutically acceptable salt: ##STR1## wherein A is an ethylene group, a vinylene group or an ethynylene group, R is a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.1-10 alkenyl group, a substituted or unsubstituted C.sub.1-10 alkynyl group, a substituted or unsubstituted C.sub.3-8 cycloalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryloxy group, Q is a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.1-10 alkenyl group, a substituted or unsubstituted C.sub.1-10 alkynyl group, a substituted or unsubstituted C.sub.3-8 cycloalkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group.

Abstract: In an ion beam irradiating apparatus for providing a neutralized ion beam to a sample, there are provided an ion source, an accelerating device and an ion beam selecting device to which the accelerated and selection ion beam is irradiated.

Abstract: A 6-fluoroprostaglandin having the formula: ##STR1## wherein A is a carbonyl group or a hydroxymethylene group, R.sup.1 is a substituted or unsubstituted C.sub.1 -C.sub.10 alkyl group or a substituted or unsubstituted 5- or 6-membered cycloalkyl group, R.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group, each of R.sup.3 and R.sup.4 which may be the same or different is a hydrogen atom or a protecting group, R.sup.5 is a hydrogen atom or a hydroxyl group, and is a single bond or a double bond, and its salt when R.sup.2 is a hydrogen atom.